FINANCIAL INFORMATION

•

•

•

•

US$7.5 million increase of share-based compensation expense, primarily attributable to our
increased headcount and higher share price;

US$3.2 million increase of materials and reagent expenses, mainly in connection with the
in-house manufacturing of drug candidates used for clinical purposes, that were previously
outsourced and recorded as external cost;

US$4.1 million increase of consulting fees, which was mainly attributable to increased
scientific,
in connection with the
advancement of our pipeline; and

regulatory and development consulting activities,

US$2.6 million increase of facilities, office expense, rental fee and other expenses to
support the growth of our organization.

Selling, General and Administrative Expense

Selling, general and administrative expense increased by US$20.1 million, or 230%, to US$28.9
million for the three months ended March 31, 2018, from US$8.8 million for the three months ended
March 31, 2017. The increase was primarily attributable to the following:

•

•

•

•

US$8.9 million increase of employee salary and benefits, which was primarily attributable
to the hiring of more personnel to support our growing organization, including the acquired
workforce in the acquisition of Celgene’s China operations;

US$3.9 million increase of share-based compensation expense, primarily attributable to our
increased headcount and higher share price;

US$1.5 million increase of professional fees for legal, consulting, recruiting, accounting
and audit services to support our growing business; and

US$5.8 million increase of selling, facility, conference fees, travel expenses, rental fees
and other administrative expenses, primarily attributable to the global expansion of our
business, including the post-combination cost of our commercial operations in China.

Interest Income, Net

Interest income (net) increased by US$1.4 million for the three months ended March 31, 2018,
as compared to the three months ended March 31, 2017. The increase in interest income was primarily
attributable to interest income on our larger cash and short-term investment balances.

Other Income, Net

Other income, net, decreased by US$0.2 million to US$0.7 million for the three months ended
March 31, 2018, from US$0.9 million for the three months ended March 31, 2017. The decrease was
mainly attributable to the impact of foreign currency exchange and related net gains.

— 272 —

